Vera Therapeutics stock declines amid broader market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Source: Benzinga
Vera Therapeutics, Inc. shares fell by 12.56% as the stock crossed below its 5-day SMA, reflecting a significant decline in investor confidence.
The decline in Vera's stock price occurred amid broader market weakness, with the Nasdaq-100 down 1.12% and the S&P 500 down 0.07%. This suggests a sector rotation, as investors may be reallocating their portfolios away from biotech stocks in response to market conditions.
This movement could indicate a shift in investor sentiment towards more stable sectors, potentially impacting Vera's future performance as it navigates through a challenging market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VERA
Wall Street analysts forecast VERA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 40.130
Low
33.00
Averages
74.08
High
100.00
Current: 40.130
Low
33.00
Averages
74.08
High
100.00
About VERA
Vera Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TRUTAKNA Receives FDA Accelerated Approval for IgAN Treatment
- FDA Accelerated Approval: Vera Therapeutics' TRUTAKNA (atacicept-vymj) has received FDA accelerated approval to reduce proteinuria in adults with IgA nephropathy at risk for disease progression, marking a significant milestone in treatment options.
- Clinical Trial Results: In the prespecified interim analysis of the ORIGIN 3 trial, participants treated with TRUTAKNA achieved a 46% reduction in proteinuria from baseline at 36 weeks, demonstrating statistical significance (p<0.0001) compared to placebo, indicating clinical relevance.
- Patient Safety: TRUTAKNA was generally well tolerated among 428 patients, with the most common adverse reactions being infections (32%) and local administration reactions (30%), most of which were mild to moderate and did not lead to treatment interruption.
- Future Outlook: While the accelerated approval is based on proteinuria reduction, it remains unestablished whether TRUTAKNA can slow long-term kidney function decline in IgAN patients, with continued approval potentially contingent on further verification from the ongoing ORIGIN 3 trial.
See More
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA
- FDA Accelerated Approval: Vera Therapeutics announced that its drug TRUTAKNA (atacicept-vymj) received FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, marking a significant advancement in the biotechnology sector.
- Clinical Trial Results: In the interim analysis of the ORIGIN 3 trial, participants treated with TRUTAKNA achieved a 46% reduction in proteinuria at 36 weeks, significantly outperforming the 42% reduction observed in the placebo group, demonstrating the drug's clinical efficacy.
- Market Potential: According to Future Market Insights Inc., the IgAN market is projected to reach $50.38 billion by 2026 and $107.23 billion by 2036, positioning TRUTAKNA to capture a significant share in this rapidly growing market.
- Competitive Landscape: TRUTAKNA enters a competitive IgAN market with key rivals including Travere Therapeutics' Filspari and Calliditas Therapeutics' Tarpeyo, necessitating ongoing clinical validation for Vera to secure its market position.
See More
Freedom Holding Corp Sees Surge in Options Trading Volume
- Surge in Options Volume: Freedom Holding Corp (FRHC) recorded an options trading volume of 1,814 contracts today, equivalent to approximately 181,400 shares, which represents about 90.2% of its average daily trading volume over the past month, indicating a significant increase in market interest.
- High Demand for Puts: Specifically, the $120 strike put option expiring on December 18, 2026, saw 1,158 contracts traded today, representing around 115,800 underlying shares, suggesting that investors are increasingly anticipating a decline in the stock's price.
- GFL Environmental Options Activity: Concurrently, GFL Environmental Inc (GFL) experienced an options trading volume of 32,857 contracts today, translating to approximately 3.3 million shares, which accounts for about 88.4% of its average daily trading volume over the past month, reflecting strong market activity.
- Strong Demand for Puts: For GFL, the $35 strike put option expiring on August 21, 2026, recorded a trading volume of 10,856 contracts today, representing about 1.1 million shares, indicating a cautious outlook from investors regarding the stock's future performance.
See More
Vera Therapeutics' Trutakna Receives FDA Approval for IgAN
- FDA Approval: Vera Therapeutics' Trutakna (atacicept-vymj) has received FDA approval aimed at reducing proteinuria in IgAN patients, marking a significant advancement in the treatment of this serious disease.
- Clinical Trial Results: Data from the ongoing Phase 3 Origin trial involving 428 patients indicate that those treated with Trutakna achieved a 46% reduction in proteinuria over nine months, demonstrating significant efficacy.
- Positive Market Reaction: Following the FDA approval, Vera Therapeutics' stock surged 7% on Tuesday, becoming one of the top trending tickers on Stocktwits, reflecting strong investor confidence in the drug.
- Addressing Patient Needs: The launch of Trutakna is seen as an innovative solution to the unmet medical needs of IgAN patients, with the CEO of Vera Therapeutics stating that the drug has the potential to improve patient care.
See More
Vera Therapeutics' Kidney Therapy Receives FDA Approval
- FDA Accelerated Approval: Vera Therapeutics' kidney disease therapy atacicept has received accelerated approval from the FDA, marking a significant advancement in treating primary immunoglobulin A nephropathy (IgAN) and potentially enhancing the company's competitive position in the biopharmaceutical sector.
- Product Launch Details: The new drug, branded as Trutakna, will be available as a once-weekly injectable aimed at reducing proteinuria in adult IgAN patients, addressing the growing market demand for effective treatment options and likely attracting more patients to this therapy.
- Market Outlook: The FDA's approval was based on a priority review of atacicept, indicating its potential in clinical trials; if positive results emerge from ongoing confirmatory studies, it will further solidify its position in the kidney disease treatment market.
- Risks and Challenges: Despite the FDA's approval, the continued availability of the drug in the U.S. will depend on the outcomes of ongoing confirmatory studies, and unfavorable results could negatively impact the company's market performance.
See More
Vera Therapeutics' Atacicept FDA Decision Approaches, Stock Rises
- FDA Decision Approaching: The U.S. FDA is set to announce its decision on Atacicept on July 7, which is aimed at treating IgA nephropathy; if approved, it will enable patients to self-administer injections at home, significantly enhancing patient quality of life.
- Clinical Trial Success: Atacicept has met its primary and key secondary goals in prior trials, significantly reducing proteinuria and stabilizing kidney function, with long-term data showing continued improvements in disease markers and a favorable safety profile, boosting market confidence in its future prospects.
- Regulatory Progress: Vera Therapeutics announced last month that the FDA agreed to an earlier analysis plan for its Phase 3 Origin 3 trial, with key kidney function data expected in Q3 2026; if results are positive, the company plans to file a supplemental Biologics License Application in Q4 2026, further enhancing market expectations.
- Optimistic Market Sentiment: Vera's shares jumped 9% in pre-market trading on Monday, reflecting bullish sentiment among investors who believe that FDA approval could drive the stock price to $60, representing a 35% upside from current levels, despite a decline of over 15% this year.
See More
TRUTAKNA Receives FDA Accelerated Approval for IgAN Treatment
- FDA Accelerated Approval: Vera Therapeutics' TRUTAKNA (atacicept-vymj) has received FDA accelerated approval to reduce proteinuria in adults with IgA nephropathy at risk for disease progression, marking a significant milestone in treatment options.
- Clinical Trial Results: In the prespecified interim analysis of the ORIGIN 3 trial, participants treated with TRUTAKNA achieved a 46% reduction in proteinuria from baseline at 36 weeks, demonstrating statistical significance (p<0.0001) compared to placebo, indicating clinical relevance.
- Patient Safety: TRUTAKNA was generally well tolerated among 428 patients, with the most common adverse reactions being infections (32%) and local administration reactions (30%), most of which were mild to moderate and did not lead to treatment interruption.
- Future Outlook: While the accelerated approval is based on proteinuria reduction, it remains unestablished whether TRUTAKNA can slow long-term kidney function decline in IgAN patients, with continued approval potentially contingent on further verification from the ongoing ORIGIN 3 trial.
See More
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA
- FDA Accelerated Approval: Vera Therapeutics announced that its drug TRUTAKNA (atacicept-vymj) received FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, marking a significant advancement in the biotechnology sector.
- Clinical Trial Results: In the interim analysis of the ORIGIN 3 trial, participants treated with TRUTAKNA achieved a 46% reduction in proteinuria at 36 weeks, significantly outperforming the 42% reduction observed in the placebo group, demonstrating the drug's clinical efficacy.
- Market Potential: According to Future Market Insights Inc., the IgAN market is projected to reach $50.38 billion by 2026 and $107.23 billion by 2036, positioning TRUTAKNA to capture a significant share in this rapidly growing market.
- Competitive Landscape: TRUTAKNA enters a competitive IgAN market with key rivals including Travere Therapeutics' Filspari and Calliditas Therapeutics' Tarpeyo, necessitating ongoing clinical validation for Vera to secure its market position.
See More
Freedom Holding Corp Sees Surge in Options Trading Volume
- Surge in Options Volume: Freedom Holding Corp (FRHC) recorded an options trading volume of 1,814 contracts today, equivalent to approximately 181,400 shares, which represents about 90.2% of its average daily trading volume over the past month, indicating a significant increase in market interest.
- High Demand for Puts: Specifically, the $120 strike put option expiring on December 18, 2026, saw 1,158 contracts traded today, representing around 115,800 underlying shares, suggesting that investors are increasingly anticipating a decline in the stock's price.
- GFL Environmental Options Activity: Concurrently, GFL Environmental Inc (GFL) experienced an options trading volume of 32,857 contracts today, translating to approximately 3.3 million shares, which accounts for about 88.4% of its average daily trading volume over the past month, reflecting strong market activity.
- Strong Demand for Puts: For GFL, the $35 strike put option expiring on August 21, 2026, recorded a trading volume of 10,856 contracts today, representing about 1.1 million shares, indicating a cautious outlook from investors regarding the stock's future performance.
See More
Vera Therapeutics' Trutakna Receives FDA Approval for IgAN
- FDA Approval: Vera Therapeutics' Trutakna (atacicept-vymj) has received FDA approval aimed at reducing proteinuria in IgAN patients, marking a significant advancement in the treatment of this serious disease.
- Clinical Trial Results: Data from the ongoing Phase 3 Origin trial involving 428 patients indicate that those treated with Trutakna achieved a 46% reduction in proteinuria over nine months, demonstrating significant efficacy.
- Positive Market Reaction: Following the FDA approval, Vera Therapeutics' stock surged 7% on Tuesday, becoming one of the top trending tickers on Stocktwits, reflecting strong investor confidence in the drug.
- Addressing Patient Needs: The launch of Trutakna is seen as an innovative solution to the unmet medical needs of IgAN patients, with the CEO of Vera Therapeutics stating that the drug has the potential to improve patient care.
See More
Vera Therapeutics' Kidney Therapy Receives FDA Approval
- FDA Accelerated Approval: Vera Therapeutics' kidney disease therapy atacicept has received accelerated approval from the FDA, marking a significant advancement in treating primary immunoglobulin A nephropathy (IgAN) and potentially enhancing the company's competitive position in the biopharmaceutical sector.
- Product Launch Details: The new drug, branded as Trutakna, will be available as a once-weekly injectable aimed at reducing proteinuria in adult IgAN patients, addressing the growing market demand for effective treatment options and likely attracting more patients to this therapy.
- Market Outlook: The FDA's approval was based on a priority review of atacicept, indicating its potential in clinical trials; if positive results emerge from ongoing confirmatory studies, it will further solidify its position in the kidney disease treatment market.
- Risks and Challenges: Despite the FDA's approval, the continued availability of the drug in the U.S. will depend on the outcomes of ongoing confirmatory studies, and unfavorable results could negatively impact the company's market performance.
See More
Vera Therapeutics' Atacicept FDA Decision Approaches, Stock Rises
- FDA Decision Approaching: The U.S. FDA is set to announce its decision on Atacicept on July 7, which is aimed at treating IgA nephropathy; if approved, it will enable patients to self-administer injections at home, significantly enhancing patient quality of life.
- Clinical Trial Success: Atacicept has met its primary and key secondary goals in prior trials, significantly reducing proteinuria and stabilizing kidney function, with long-term data showing continued improvements in disease markers and a favorable safety profile, boosting market confidence in its future prospects.
- Regulatory Progress: Vera Therapeutics announced last month that the FDA agreed to an earlier analysis plan for its Phase 3 Origin 3 trial, with key kidney function data expected in Q3 2026; if results are positive, the company plans to file a supplemental Biologics License Application in Q4 2026, further enhancing market expectations.
- Optimistic Market Sentiment: Vera's shares jumped 9% in pre-market trading on Monday, reflecting bullish sentiment among investors who believe that FDA approval could drive the stock price to $60, representing a 35% upside from current levels, despite a decline of over 15% this year.
See More
